<?xml version="1.0" encoding="UTF-8"?>
<p>Neurologists therefore need to be involved in the care of patients with COVID‐19 and provide a more comprehensive picture of the spectrum of nervous system manifestations [
 <xref rid="ene14278-bib-0008" ref-type="ref">8</xref>]. Then, the bed‐to‐benchside approach with development of animal models for CoV‐2, which resemble human CNS infection, should have high priority. Such a model would not only enable the development of preventive strategies (e.g. blocking viral entry to the CNS) but also provide a mode to study therapies aimed at limiting brain injury and subsequent neurological sequelae. Some of the pre‐clinical preparatory work for this step has been done.
</p>
